Home / Blog / M&A Fundamentals

How to Sell a Healthcare Business in Asia Pacific

How to sell a healthcare business in Asia Pacific — valuation multiples, who the buyers are, and how confidential AI matching finds qualified investors.

Healthcare businesses in Asia Pacific attract strong buyer demand, premium valuation multiples, and significant cross-border interest. But selling a healthcare business — whether a clinic network, diagnostic chain, aged care facility, or digital health platform — involves regulatory complexity that most business sales do not.

This guide covers who the buyers are, what they pay, and how to run a confidential sale process in APAC’s healthcare sector.

Amafi is a confidential M&A matching marketplace for healthcare business owners. Your business is matched privately to qualified buyers — strategic acquirers, PE funds, and healthcare conglomerates — without a public listing. See who would buy your business →


Who Buys Healthcare Businesses in Asia Pacific

Buyer demand for APAC healthcare assets comes from four distinct pools:

Regional healthcare conglomerates — groups such as IHH Healthcare (Malaysia/Singapore), Raffles Medical, Bumrungrad International, and Apollo Hospitals are actively acquiring to expand geographic and service footprint. These buyers value patient volume, doctor networks, and brand in specific geographies. They typically pay the highest multiples for premium assets that extend an existing platform.

Private equity funds — healthcare-focused PE (KKR Asia Healthcare, Temasek, Quadrant, Affinity Equity Partners) and generalist funds with healthcare allocations are active acquirers across the region. PE targets businesses with EBITDA of SGD/AUD 3M+ and a clear growth story: expansion into new markets, consolidation opportunity, or technology-enabled services.

Global strategic acquirers — multinationals in diagnostics (Sonic Healthcare, Quest Diagnostics), medical devices, and health technology look at APAC for market entry or scale. These buyers seek market-leading positions and established reimbursement relationships.

Family offices and private capital — Singapore, Hong Kong, and Indonesia family offices are increasing healthcare allocations, particularly in essential services (aged care, primary care) and healthcare real estate. Deal sizes tend to be smaller ($10M–$50M) and buyer criteria more flexible.


Healthcare Business Valuation Multiples in APAC

Multiples vary significantly by sub-sector and market maturity:

Sub-sectorTypical EBITDA multipleKey drivers
Hospital and day surgery groups8–14xBed count, specialist accreditation, government contracts
Specialty clinic networks (dental, ophthalmology)6–10xPatient panel size, recurring revenue, GP referral relationships
Aged care and disability services7–12xGovernment funding dependency, occupancy rate, staff stability
Diagnostic and pathology chains6–9xVolume, equipment modernity, accreditation, network reach
Primary care / GP clinics5–8xRegistered patient list, bulk billing mix, doctor tenure
Digital health and health tech3–6x ARRARR growth, churn, contract structure

Multiples represent a range observed in APAC healthcare transactions 2023–2025. Individual deals vary based on quality, size, and market conditions.

Premium multiples are achievable when the business has a documented growth track record, recurring revenue from contracts or registered patient panels, government or insurer reimbursement relationships, and clean regulatory standing across all licences.


What Buyers Examine in Healthcare Due Diligence

Healthcare due diligence goes deeper than financial reporting alone. Buyers will examine:

Regulatory and licensing. Every jurisdiction in APAC has different healthcare licensing bodies. Clinic and hospital operators need to confirm all licences are current, transferable on a change of control, and free of pending regulatory actions. In Australia, AHPRA accreditation matters. In Singapore, MOH licensing. In Thailand, FDA and health ministry approvals. Change-of-control consents may be required before closing.

Clinical governance. Buyers — particularly PE and strategic acquirers — will assess accreditation records (JCI, ACHS, or local equivalents), complaints and incident history, and quality improvement processes. A clean clinical governance record materially reduces risk discount in valuation.

Reimbursement and payor relationships. The stability of government bulk-billing agreements (Australia), panel doctor contracts (Singapore), or insurance reimbursement arrangements is a core value driver. Concentration risk — dependency on a single payor — is a red flag buyers will price heavily.

Key person risk. If the business’s revenue depends on a specific doctor or specialist, buyers will want to understand succession, earn-out structures, or employment commitments post-close. Many healthcare deals include provisions to retain founding clinicians for 12–24 months post-acquisition.

IT and data systems. Patient management systems, clinical record integrity, and data privacy compliance (Australian Privacy Act, PDPA Singapore, PDPO Hong Kong) are reviewed in every regulated healthcare transaction.


Preparing Your Healthcare Business for Sale

The businesses that achieve premium multiples and shorter deal timelines share three characteristics:

Financial clarity. Three years of audited or reviewed financial statements. Normalised EBITDA (removing owner distributions, one-off expenses, and related-party items). Revenue split by service type, payor, and geography. Buyers will rebuild these numbers themselves — having them prepared reduces friction and signals quality.

Clean regulatory standing. All licences current and in good standing. No pending regulatory investigations. Accreditation certificates up to date. Change-of-control provisions in government contracts reviewed in advance so you know what approvals are required at closing.

Strong clinical and operational management. Buyers pay a control premium for businesses that can operate without the founding owner. Demonstrating that clinical and operational management can function independently — documented protocols, stable senior staff, and management accounts reviewed by the team — reduces key-person discount at valuation.

Preparation typically takes 6–12 months. Owners who start a year before their target sale timeline consistently achieve better outcomes than those who start the process reactively.


Running a Confidential Sale Process

Healthcare business sales require careful confidentiality management. Unlike general businesses, a healthcare sale that becomes known to employees, patients, or referring doctors can directly impair the business’s performance and negotiating position before a deal closes.

Key confidentiality mechanisms:

  1. No public listings. Never list on a business broker marketplace. Healthcare buyers of scale do not search these platforms; you attract the wrong audience and expose your business unnecessarily.
  2. Blind teasers. Initial buyer outreach uses an anonymised profile — industry, geography, and financial summary only — with no identifying information. Interested buyers sign an NDA before the full profile is shared.
  3. Controlled information flow. Full financial, operational, and clinical due diligence materials are shared only with buyers who have signed a confidentiality agreement and been pre-qualified against your criteria.
  4. Intermediary management. Using an M&A advisor or AI-matched platform as an intermediary means buyers engage with the process first — not with you directly — until you choose to proceed.

“Healthcare assets in APAC are attracting cross-border PE and strategic interest at levels we haven’t seen before — but the complexity of change-of-control licensing means founders who run a thoughtful, confidential process consistently outperform those who rush the market.” — Daniel Bae, Founder & CEO, Amafi (with $30B+ in transaction experience across APAC)


Finding Buyers Without Going Public

Amafi is a confidential M&A matching marketplace for healthcare business owners who want to explore a sale on their own terms.

How it works:

  1. Register your business on Amafi with details about your sector, geography, and deal preferences.
  2. Amafi’s AI matches your profile privately against qualified investors — PE funds, strategic acquirers, family offices — that have registered matching criteria.
  3. You receive a notification that a matched buyer exists. No information about your business is shared until you approve the introduction.
  4. Once you approve, both sides receive enough information to assess interest — without a public listing or competitive auction.
  5. A licensed M&A advisor through Lyndon Advisory manages the formal transaction process once both sides are aligned.

There is no fee to register. Amafi’s success fee is paid through the advisory process on a completed deal.

See who would buy your healthcare business →


Daniel Bae

About the author

Daniel Bae

Founder & CEO, Amafi

Daniel is an investment banker with 15+ years of experience in M&A, having advised on deals worth over US$30 billion. His career spans Citi, Moelis, Nomura, and ANZ across London, Hong Kong, and Sydney. He holds a combined Commerce/Law degree from the University of New South Wales. Daniel founded Amafi to solve the pain points in M&A, enabling bankers to focus on what matters most — delivering trusted advice to clients.